Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI

International Clinical Psychopharmacology

Volumn 26, Issue 4, 2011, Pages 206-212

  Bitran, Stella ^a   Farabaugh, Amy H ^a   Ameral, Victoria E ^a   LaRocca, Rachel A ^a   Clain, Alisabet J ^a   Fava, Maurizio ^a   Mischoulon, David ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressants; Anxiety; Depression; Predictors; Remission; St John's wort

Indexed keywords

FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; PLACEBO; SERTRALINE;

ANXIETY; ARTICLE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SOMATIZATION; TREATMENT OUTCOME;

DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; HYPERICUM; LOGISTIC MODELS; OUTPATIENTS; PHYTOTHERAPY; PLANT PREPARATIONS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 80051544899     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328343ba08     Document Type: Article

References (36)

1. Astin J (1998). Why patients use alternative medicine: results of a national study. JAMA 279:1548-1553. (Pubitemid 28233010)
2. Bech P (2001). Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 4:337-345. (Pubitemid 33151677)
3. Coryell W, Coppen A, Zeigler VE, Biggs JT (1982). Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychol Med 12:135-139. (Pubitemid 12126806)
4. Downing RW, Rickels K (1985). Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatr Scand 72:522-528. (Pubitemid 16175949)
5. Dunner DL, Goldstein D J, Mallinckrodt C, Lu Y, Detke MJ (2003). Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 18:53-61. (Pubitemid 37175581)
6. Farabaugh A, Mischoulon D, Fava M,Wu SL, Mascarini A, Tossani E, et al. (2005). The relationship between early changes in the HAM-D-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol 20:87-91. (Pubitemid 40354397)
7. Farabaugh AH, Bitran S,Witte J, Alpert J, Chuzi S, Clain AJ, et al. (2010). Anxious depression and early changes in the HAM-D-17 anxiety/somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. [Epub ahead of print]
8. Fava M, Rankin MA,Wright EC, Alpert JE, Nierenberg AA, Pava J, Rosenbaum JF (2000a). Anxiety disorders in major depression. Compr Psychiatry 41:97-102. (Pubitemid 30149018)
9. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME (2000b). Fluoxetine versus sertraline and paroxotine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59:119-126. (Pubitemid 30317428)
10. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. (2005). A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 25:441-447. (Pubitemid 41368366)
11. Fava M, Rush AJ, Alpert JE, Balasubramani GK,Wisniewski SR, Carmin CN, et al. (2008). Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165:342-351. (Pubitemid 351704490)
12. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas G (2010). Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry 71:682-688.
13. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
14. Henkel V, Seemü ller F, Obermeier M, Adli M, Bauer M, Mundt C, et al. (2009). Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115:439-449.
15. Hypericum Depression Trial Study Group (2002). Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 287:1807-1814.
16. Katz MM, Tekell JL, Bowden CL, Brannon S, Houston JP, Berman N, Frazer A (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29:566-579. (Pubitemid 38365934)
17. Katz MM, Meyers AL, Prakash A, Gaynor PJ, Houston JP (2009). Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull 42:94-107.
18. Khan A, Khan SR, Walens G, Kolts R, Giller EL (2003). Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28:552-557.
19. Kieser M, Szegedi A (2005). Predicting stable treatment response in patients with major depression treated with Hypericum extract WS 5570/5572. Pharmacopsychiatry 38:194-200. (Pubitemid 41414864)
20. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE (2009). Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 10:927-936.
21. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
22. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (1996). St John's wort for depression: an overview and meta-analysis of randomized clinical trials. BMJ 313:253-258. (Pubitemid 26254730)
23. Linde K, Berner MM, Kriston L (2008). St John's wort for major depression. Cochrane Database Syst Rev 4:CD000448.
24. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, et al. (2006). Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 163:1542-1548. (Pubitemid 44465753)
25. Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H (2010). Accelerating response to antidepressant treatment in depression: a review and clinicalsuggestions. Prog Neuropsychopharmacol Biol Psychiatry 34:259-264.
26. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M (1995). Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152:1500-1503.
27. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M (2000). Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157:1423-1428.
28. Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984). Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 41:782-786. (Pubitemid 14092257)
29. Rynn M, Khalid-Khan S, Garcia-Espana JF, Etemad B, Rickels K (2006). Early response and 8-week treatment outcome in GAD. Depress Anxiety 23:461-465. (Pubitemid 44917664)
30. Small GW, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB (1995). Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. IntPsychogeriatr 7 (Suppl):41-53.
31. Stassen HH, Delini-Stula A, Angst J (1993). Time course of improvement under antidepressant treatment: a survival analytical approach. Eur Neuropsychopharmacol 3:127-135. (Pubitemid 24089502)
32. Szegedi A, Mü ller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64:413-420. (Pubitemid 36547285)
33. Szegedi A, Jansen WT, Van Willigenburg AP, Van der Meulen E, Stassen HH, Thase ME (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a metaanalysisincluding 6562 patients. J Clin Psychiatry 70:344-353.
34. Tadić A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V, Hegerl U (2010). Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord 120: 86-93.
35. Tollefson GD, Holman SL (1994). How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 9:245-250. (Pubitemid 24374885)
36. Wade AG, Schlaepfer TE, Andersen HF, Kilts CD (2009). Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res 43:568-575.